Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Aliki I. Venetsanopoulou, Paraskevi V. Voulgari & Alexandros A. Drosos. (2022) Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis. Expert Review of Clinical Immunology 18:5, pages 485-493.
Read now
Read now
Diego Sangiorgi, Maurizio Benucci, Carmela Nappi, Valentina Perrone, Stefano Buda & Luca Degli Esposti. (2015) Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis. Biologics: Targets and Therapy 9, pages 119-127.
Read now
Read now
Machaon Bonafede, Barbara H. Johnson, Nicole Princic, Neel Shah & David J. Harrison. (2015) Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. Journal of Medical Economics 18:5, pages 376-389.
Read now
Read now
Jeffrey R. Curtis, Vernon F. Schabert, Jason Yeaw, Jonathan R. Korn, Caroleen Quach, David J. Harrison, Huifeng Yun, George J. Joseph & David Collier. (2014) Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis. Journal of Medical Economics 17:8, pages 555-566.
Read now
Read now
Zayrho Desanvicente-Celis, Julian Caro-Moreno, Mateo Enciso-Zuluaga & Juan-Manuel Anaya. (2013) Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases. Biosimilars 3, pages 1-17.
Read now
Read now
Machaon Bonafede, George J. Joseph, Nicole Princic & David J. Harrison. (2013) Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. Journal of Medical Economics 16:9, pages 1120-1128.
Read now
Read now
Maxine D. Fisher, Crystal Watson, Kathleen M. Fox, Yen-Wen Chen & Shravanthi R. Gandra. (2013) Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population. Current Medical Research and Opinion 29:5, pages 561-568.
Read now
Read now
Chureen T. Carter, Arun K. Changolkar & R. Scott McKenzie. (2012) Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. Journal of Medical Economics 15:2, pages 332-339.
Read now
Read now
Vernon F. Schabert, Crystal Watson, Shravanthi R. Gandra, Seth Goodman, Kathleen M. Fox & David J. Harrison. (2012) Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. Journal of Medical Economics 15:2, pages 264-275.
Read now
Read now
Jan Norum, Wenche Koldingsnes, Torfinn Aanes, Margaret Aarag Antonsen, Jon Florholmen & Masahide Kondo. (2011) The economic burden of TNFα inhibitors and other biologic treatments in Norway. ClinicoEconomics and Outcomes Research 3, pages 73-78.
Read now
Read now
Eric Wu, Lei Chen, Howard Birnbaum, Elaine Yang & Mary Cifaldi. (2008) Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Current Medical Research and Opinion 24:8, pages 2229-2240.
Read now
Read now
Dafna D Gladman & Ruth E Brown. (2008) Pharmacoeconomics of adalimumab for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease. Expert Review of Pharmacoeconomics & Outcomes Research 8:2, pages 111-125.
Read now
Read now
Articles from other publishers (20)
Andrew Hresko, Tzu-Chieh Lin & Daniel H. Solomon. (2018) Medical Care Costs Associated With Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-Analysis. Arthritis Care & Research 70:10, pages 1431-1438.
Crossref
Crossref
Aniket A. Kawatkar, Joel W. Hay, William Stohl & Michael B. Nichol. (2018) Consistent estimation of polychotomous treatment effects with selection-bias and unobserved heterogeneity using panel data correlated random coefficients model. Health Services and Outcomes Research Methodology 18:2, pages 75-95.
Crossref
Crossref
Anagha Nadkarni, Donna McMorrow, Chad Patel, Robert Fowler & David Smith. (2017) Incidence of dose escalation and impact on biologic costs among patients with rheumatoid arthritis treated with three intravenous agents. Journal of Comparative Effectiveness Research 6:8, pages 671-682.
Crossref
Crossref
Tore K Kvien, Maria Greenwald, Paul M Peloso, Hongwei Wang, Anish Mehta & Arnold Gammaitoni. (2015) Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical trial with etoricoxib. BMC Musculoskeletal Disorders 16:1.
Crossref
Crossref
Ning Wu, Yuan-Chi (Daisy) Lee, Neel Shah & David J. Harrison. (2014) Cost of Biologics per Treated Patient across Immune-mediated Inflammatory Disease Indications in a Pharmacy Benefit Management Setting: A Retrospective Cohort Study. Clinical Therapeutics 36:8, pages 1231-1241.e3.
Crossref
Crossref
Alejandro González Álvarez, Manuel Gómez Barrera, Joaquín Borrás Blasco & Emilio José Giner Serret. (2014) Adalimumab and Etanercept in the Treatment of Rheumatoid Arthritis and Spondyloarthropathies: Budget Impact Model of Dose Reduction. Journal of Pharmacy and Nutrition Sciences 4:3, pages 170-176.
Crossref
Crossref
Sebastian Braun, Jan Zeidler, Roland Linder, Susanne Engel, Frank Verheyen & Wolfgang Greiner. (2012) Treatment costs of attention deficit hyperactivity disorder in Germany. The European Journal of Health Economics 14:6, pages 939-945.
Crossref
Crossref
Aniket A. Kawatkar, Joel W. Hay, William Stohl & Michael B. Nichol. (2012) INCREMENTAL EXPENDITURE OF BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC TREATMENT USING INSTRUMENTAL VARIABLES IN PANEL DATA. Health Economics 22:7, pages 807-823.
Crossref
Crossref
Maria Goutsou, Ozgecan Uluscu, Angela Amend Kwasnik, Robert Stianchi, Paul M Peloso & Gillian Cannon. (2013) Biologics utilization for rheumatoid arthritis in the United States: An observational longitudinal study. Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing 13:2, pages 74-81.
Crossref
Crossref
Steven W. Blume, Kathleen M. Fox, George Joseph, Chien-Chia Chuang, Jessy Thomas & Shravanthi R. Gandra. (2013) Tumor Necrosis Factor-Blocker Dose Escalation in Rheumatoid Arthritis Patients in a Pharmacy Benefit Management Setting. Advances in Therapy 30:5, pages 517-527.
Crossref
Crossref
Zayrho Desanvicente-Celis, Arley Gomez-Lopez & Juan-Manuel Anaya. (2012) Similar biotherapeutic products: overview and reflections. Immunotherapy 4:12, pages 1841-1857.
Crossref
Crossref
Jan Zeidler, Thomas Mittendorf, Rüdiger Müller & Johannes von Kempis. (2012) Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective. Health Economics Review 2:1.
Crossref
Crossref
Aniket A. Kawatkar, Steven J. Jacobsen, Gerald D. Levy, Swati S. Medhekar, Kumarapuram V. Venkatasubramaniam & Lisa J. Herrinton. (2012) Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey. Arthritis Care & Research 64:11, pages 1649-1656.
Crossref
Crossref
Machaon M. K. Bonafede, Shravanthi R. Gandra, Crystal Watson, Nicole Princic & Kathleen M. Fox. (2012) Cost per Treated Patient for Etanercept, Adalimumab, and Infliximab Across Adult Indications: a Claims Analysis. Advances in Therapy 29:3, pages 234-248.
Crossref
Crossref
STEPHAN McBRIDE, KHALED SARSOUR, LEIGH ANN WHITE, DAVID R. NELSON, ANITA J. CHAWLA & JOSEPH A. JOHNSTON. (2011) Biologic Disease-modifying Drug Treatment Patterns and Associated Costs for Patients with Rheumatoid Arthritis. The Journal of Rheumatology 38:10, pages 2141-2149.
Crossref
Crossref
Jeffrey R. Curtis & Jasvinder A. Singh. (2011) Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care. Clinical Therapeutics 33:6, pages 679-707.
Crossref
Crossref
James C. Robinson. (2010) Applying Value-Based Insurance Design To High-Cost Health Services. Health Affairs 29:11, pages 2009-2016.
Crossref
Crossref
M. Benucci, F. Li Gobbi, L. Sabadini, G. Saviola, P. Baiardi & M. Manfredi. (2009) The Economic Burden of Biological Therapy in Rheumatoid Arthritis in Clinical Practice: Cost-Effectiveness Analysis of Sub-Cutaneous Anti-TNFα Treatment in Italian Patients. International Journal of Immunopathology and Pharmacology 22:4, pages 1147-1152.
Crossref
Crossref
Daniel Polsky, Daria Eremina, Gregory Hess, Jerrold Hill, Scott Hulnick, Adam Roumm, Joanna L. Whyte & Joel Kallich. (2009) The Importance of Clinical Variables in Comparative Analyses Using Propensity-Score Matching. PharmacoEconomics 27:9, pages 755-765.
Crossref
Crossref
Daniel A. Ollendorf, David Klingman, Elisabeth Hazard & Saurabh Ray. (2009) Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clinical Therapeutics 31:4, pages 825-835.
Crossref
Crossref